DIRS.INFO The most relevant business & tech news

☆ Goldman says this little-known biotech stock could more than double
▼ + stars: | 2023-08-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Clinical-stage biopharmaceutical company Sagimet Biosciences could see its treatments reach a breakout stage, which could send its share price soaring, according to Goldman Sachs. The stock has been publicly traded since July 14, and it's trading slightly below its IPO level. Investors are focused on upcoming biopsy results of the second phase of the denifanstat study on liver fat levels, said Tan. Positive results from this phase would support advancement into a pivotal phase three study, she added. The "role of FASN in other indications could offer upside," Tan noted.

Persons: Goldman Sachs, NASH, Andrea Tan, Tan, Denifanstat, FASN, — CNBC's Michael Bloom Organizations: Sagimet Biosciences

☆ Stocks making the biggest moves premarket: UPS, Lucid, Beyond Meat, Novo Nordisk and more
▼ + stars: | 2023-08-08 | by ( Brian Evans | ) www.cnbc.com time to read: +4 min

The company reported an adjusted $2.11 per share on revenue of $8.31 billion, while analysts polled by Refinitiv forecasted $1.98 and $7.58 billion. Analysts surveyed by Refinitiv had penciled in a loss of 33 cents per share on $175 million of revenue. Palantir Technologies — Palantir Technologies slid 3.4% after the data analytics company reported its second-quarter results. Beyond Meat reported an adjusted loss of 83 cents per share on $102.1 million in revenue, while Refinitiv forecasted 86 cents and $108.4 million. Paramount Global — The media conglomerate's shares climbed more than 2% in premarket trading after the company reported a quarterly earnings and revenue beat.

Persons: Goldman Sachs, NASH, Banks, Moody's, Eli Lilly, EchoStar, Charlie Ergen, Refinitiv, Lucid, Palantir, Hims, Simon & Schuster, Yun Li, Samantha Subin, Sarah Min, Pia Singh, Jesse Pound Organizations: Sagimet, Goldman, T Bank, Citizens Financial, Bank of New York Mellon, Truist, JPMorgan Chase, Telsey, Refinitiv, Novo Nordisk —, Dish, United Parcel Service, behemoth, UPS, Palantir, Paramount Global, Paramount, KKR Locations: New York, Banks —

☆ Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug
▼ + stars: | 2023-08-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. Shares of Sage Therapeutics fell more than 50% on Monday after the Food and Drug Administration approved the biotech company's oral drug zuranolone for postpartum depression, but not for major depressive disorder, a bigger potential market. The two companies also applied for approval of zuranolone for major depressive disorder, also known as clinical depression. Zuranolone had the potential for $1 billion in peak sales, compared with $250 million to $500 million for postpartum depression, Jefferies analyst Michael Yee said in a research note Sunday. He said clinical depression "was really the big upside driver here" for the companies, while postpartum depression is "much smaller and may not be hugely profitable."

Persons: Sage, Zuranolone, Jefferies, Michael Yee Organizations: Sage Therapeutics, Food and Drug Administration

☆ Trick That Helps Big Pharma Companies Avoid Paying Billons in US Taxes
▼ + stars: | 2023-08-03 | by ( Brad Setser | Tess Turner | ) www.businessinsider.com time to read: +11 min

But take a look at the corporate disclosures of America's largest pharmaceutical companies, and a puzzling hole opens. Large legal loopholesThe offshore migration of these pharmaceutical companies' profits may seem egregious, but the tax gymnastics are generally legal. On paper, America's corporate-tax rate is 21%, but the country's largest and most profitable pharmaceutical companies don't pay anything close to that. What's more, the superlow rate enjoyed by American pharmaceutical companies isn't necessary for these firms to be internationally competitive. A spoonful of medicine to make the taxes go downAmerica's pharmaceutical companies have made great contributions to medicine.

Persons: Democratic Sen, Ron Wyden, AbbVie, it's, Keytruda, Gilead, Eli Lilly, they've, Brad W, Whitney, Tess Turner Organizations: Merck, National Institutes of Health . Pharmaceutical, Democratic, Pfizer, US pharma, US Treasury, Trump, Treasury, US, Denmark's, Nordisk, Novartis, National Institutes of Health, Whitney Shepardson, Council, Foreign Relations Locations: Oregon, America, Caribbean, Europe, Bermuda, Puerto Rico, Germany, Ireland, Singapore, Switzerland, Belgium, Denmark

☆ Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more
▼ + stars: | 2023-07-24 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +4 min

Knight-Swift Transportation — The freight transportation company's shares gained more than 1%. Knight-Swift reported adjusted earnings of 49 cents per share on revenue of $1.55 billion. Intuitive Surgical reported adjusted earnings of $1.42 per share on revenue of $1.76 billion. The fast-food chain reported mixed quarterly results, including adjusted earnings of $3.08 per share, beating analysts' predictions for $3.05 per share. Spotify — The music streaming company's shares dropped 5.5% after Spotify announced price increases for its premium subscription plans.

Persons: Oppenheimer, Riley, Eric Wold, Barbie, Mike Wirth, Chevron, Swift, Domino's, Becton Dickinson, Raymond James, Gilead, Estée Lauder, Piper Sandler, — CNBC's Hakyung Kim, Yun Li, Alex Harring, Samantha Subin Organizations: AMC, Mattel, Warner Bros, Chevron, Swift Transportation, U.S . Food, Drug Administration, Sirius XM, Deutsche Bank, Nasdaq, Spotify, Gilead Sciences Locations: New York, U.S, Gilead, China

☆ Here's what Jim Cramer thinks about J&J stock after a pivotal talc case verdict
▼ + stars: | 2023-07-21 | by ( Paulina Likos | ) www.cnbc.com time to read: +7 min

But on Tuesday, J & J was ordered to pay $18.8 million after jurors found in favor of 24-year-old Emory Hernandez Valadez who claimed in his lawsuit that he developed mesothelioma, a deadly cancer linked to asbestos, from exposure to J & J talc products. J & J has said that over 60,000 claimants support its latest $8.9 billion settlement to be paid out over 25 years. Johnson & Johnson issued an official statement following the verdict in favor of Valdez, intending to appeal. Even so, J & J got a few of price target increases on Wall Street on Friday. The higher growth pharmaceuticals and medical technology businesses are remaining as the new J & J.

Persons: Johnson, J's, Jim Cramer, Jim, J, Emory Hernandez Valadez, we're, there's, Moshe Maimon, Levy, Maimon, Michael Kaplan, Kaplan, Erik Haas, Thursday's, Haas, Jim Cramer's, Justin Sullivan Organizations: Johnson, LTL Management, J, Credit Suisse, AAA, CNBC, & ' $, & $ Locations: California, American, Levy Konigsberg, Valdez, Stifel, Kenvue, San Anselmo , California

☆ Bullish developments for three stocks across sectors — and our take, too
▼ + stars: | 2023-07-21 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Morgan Stanley analysts believe the market for obesity drugs is even larger than initially expected, a finding that aligns with our rosy outlook on Eli Lilly (LLY). The news: Obesity drugs could generate annual sales up to $77 billion in 2030, Morgan Stanley said Friday, a nearly 43% increase to the firm's previous forecast. Insurance reimbursement for obesity drugs has spread quicker than Morgan Stanley expected, which helped prompt the firm to update its multiyear sales outlook. However, there's been some concern that insurance companies would be hesitant to cover this new class of obesity drugs, which carry hefty price tags, along with side effects like nausea and vomiting. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Morgan Stanley, Eli Lilly, LLY, Lilly, Wegovy, Eli Lilly's, Morgan Stanley's, Jim Cramer's, we've, there's, Sartorius, Danaher, We've, We're, Lisa Su, Su, TSM, Apple's, There's, Jim Cramer, Jim, Cristina Arias Organizations: Club, Novo Nordisk, Wall, AMD, Devices, Club holding's, Nikkei Asia, Taiwan Semiconductor Manufacturing Company, Apple, Nvidia, Intel, CNBC, Company, Pharmaceutical Locations: U.S, Japan, Tokyo, Taiwan, China, Beijing, Arizona, Alcobendas, Madrid, Spain

Overall, an FDA spokesperson says that “trial participants should reflect the population that is likely to use the product if FDA-approved. Across a group of 10 novel cancer therapies approved by the FDA in 2022, data shows the share of Black participants in key clinical trials ranged from zero to 8%. “Access to clinical trials at the sites where patients are living is an important factor to changing the landscape,” Perez says. “There’s been some novel ways to recruit patients, like using the church and using barbershops to recruit Black patients,” Cho says. Haddad says a number of Mayo patients were receiving experimental therapies through clinical trials when the pandemic began.

Persons: ”, Leslie Cho, Robert, Suzanne Tomsich, it’s, Edith Perez, Bolt Biotherapeutics, ” Perez, Eli Lilly, “, Lilly “, they’ll, Craig Lipset, ” Lipset, ” Cho, “ There’s, Dr, Tufia Haddad, Haddad, Mayo, Jennifer Dahne, Larry Hawk, Hawk Organizations: Women’s Cardiovascular, Cleveland Clinic, of Cardiovascular Medicine, U.S . Food, Drug Administration, FDA, “, Health, Committee, Cancer, Janssen Pharmaceuticals, Centers for Disease Control, Research Alliance, Mayo Clinic Comprehensive Cancer Center, Care, Mayo’s Center for Digital Health, College of Medicine, Medical University of South, of Psychology, University, Buffalo, SUNY, JAMA Locations: U.S, Chicago, Dallas, Los Angeles, Philadelphia, Los Angeles County, Alaska, “, Medical University of South Carolina

☆ Credit Suisse gives its top stock picks for the second half
▼ + stars: | 2023-07-11 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

After a strong first half for the stock market, Credit Suisse has an idea to keep the gains going. Now, questions swirl around if the market can continue its ascent as the second half of 2023 kicks into high gear. Credit Suisse asked every one of its U.S. research analysts to name their top stock picks when looking at the next six to 12 months. His price target implies shares could rally nearly 35% over the next year. International Game Technology also made the list, with analyst Ben Chaiken expecting big upside ahead even after a strong first half.

Persons: Stocks, Alcoa, Curt Woodworth, Woodworth, Refinitiv, Ben Chaiken, Judah Frommer, Frommer, MasTec, Jamie Cook, — CNBC's Michael Bloom Organizations: Credit Suisse, Nasdaq, Technology

☆ Bayer claims early lead in Parkinson's stem cell therapy
▼ + stars: | 2023-06-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

Some of this work is done by Britain's' Cambridge University, South Korea's Bundang CHA Hospital, International Stem Cell Corp's (ISCO.PK) Cyto Therapeutics in Australia, the Chinese Academy of Sciences, Harvard University and Japan's Kyoto University Hospital. For BlueRock's experimental therapy, researchers took induced pluripotent stem cells, which are modified to regain the ability to form any type of specialised tissue, and transformed them into dopamine-producing nerve cells. When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease. Initial trial results showed the cells multiplied and started making dopamine, an important brain signalling molecule which is lacking in Parkinson's patients. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.

Persons: Wolfgang Rattay, Bayer, BlueRock, Britain's, Jennifer Doudna, Ludwig Burger, Miranda Murray, Mark Potter Organizations: Bayer AG, REUTERS, Bayer, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, BlueRock Therapeutics, Mammoth Biosciences, Thomson Locations: Leverkusen, Germany, FRANKFURT, Australia, San Francisco Bay

☆ Siemens and UCLA say data compromised in MOVEit data breach
▼ + stars: | 2023-06-27 | by ( ) www.reuters.com time to read: +1 min

The hackers behind the wide-ranging breach, Cl0p, had earlier boasted about stealing data from UCLA and Siemens on their website. Cl0p also claimed to have stolen data from biopharmaceutical company Abbvie Inc (ABBV.N) and French industrial group Schneider Electric (SCHN.PA). Siemens and UCLA provided few additional details about the scope or consequences of the breach. Siemens said none of its critical data had been compromised and its operations remained unaffected. UCLA said its campus systems were unaffected and that "all of those who have been impacted have been notified".

Persons: Cl0p, Christoph Steitz, Raphael Satter, Matthias Williams, Mark Potter Organizations: Siemens Energy, University of California, UCLA, Siemens, Abbvie Inc, Schneider, FBI, Genworth, Thomson Locations: FRANKFURT, Los Angeles, UCLA

☆ Stocks making the biggest moves midday: Starbucks, CarMax, Virgin Galactic and more
▼ + stars: | 2023-06-23 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

A view of the Starbucks vending van during its debut in Hangzhou, the capital of China's Zhejiang province, June 7, 2022. Starbucks — Starbucks shares lost nearly 2.5% after a union representing workers said strikes are slated to begin Friday in response to claims the coffee shop chain is not allowing Pride decorations at cafes. More than 150 stores, and about 3,500 workers, plan to join the strike occurring over the next week, the union said. CarMax — The used-car retailer popped 10% after beating the consensus estimate of analysts for its first-quarter revenue. Virgin Galactic — Virgin Galactic shed 18% after announcing a $300 million capital raise via a common stock offering.

Persons: CarMax, Armour, Wells Fargo, TD Cowen, Morgan Stanley, Evotec, — CNBC's Michelle Fox, Alex Harring, Jesse Pound Organizations: Starbucks, StreetAccount ., Galactic, Deutsche Bank, Accenture —, Accenture, GSK — U.S, GSK Locations: Hangzhou, China's Zhejiang province, North America, Germany

☆ Stocks making the biggest moves midday: Overstock, Tesla, Accenture and more
▼ + stars: | 2023-06-22 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Accenture — The stock fell 2.6% after the consulting firm shaved the top end of its revenue expectations for the fiscal year. Darden posted earnings of $2.58 per share on revenue of $2.77 billion in its latest quarter. Tesla — Tesla shares traded flat amid a choppy session after Morgan Stanley downgraded the electric-vehicle giant to an equal weight rating from overweight, citing valuation concerns. Loop also reiterated its buy rating and raised its price target given what it sees as an opportunity for the stock to rally further. Expedia , TripAdvisor — Expedia and TripAdvisor gained 1.5% and 3.2%, respectively, after B. Riley initiated coverage on each stock as buy.

Persons: AeroSystems, Max, Darden, Eugene Lee, influencer Dylan, Tesla, Morgan Stanley, Root, JPMorgan Chase, Dow, —, TripAdvisor, Riley, Expedia, Eli Lilly —, Samantha Subin, Michelle Fox, Jesse Pound Organizations: Bed, Boeing, Accenture, Darden, FactSet, Anheuser, Busch InBev —, Deutsche Bank, NRG Energy, Wall Street, Elliott Investment Management, Embedded Insurance, Alcoa, JPMorgan, Amazon Prime, Bank of America Locations: Salt Lake City , Utah, Wichita , Kansas, Illinois

☆ This stock could become a 'one-stop shop' for biopharma and rally more than 35%, RBC says
▼ + stars: | 2023-06-21 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Avantor can show near-term resilience before outperforming in the long term, according to RBC Capital Markets. Analyst Conor McNamara initiated coverage of the health care products stock at outperform. His $27 price target implies a 37.4% upside from where shares finished Tuesday. AVTR YTD mountain Avantor Avantor is well-positioned for the long-term, McNamara said, as the life science tools sector is one of the most attractive in health care. Though the price target would require the stock to trade at historical multiples relative to peers, McNamara said that would be justified after the company's operating improvements in recent years.

Persons: Conor McNamara, McNamara, — CNBC's Michael Bloom Organizations: RBC Capital Markets

☆ CNBC Daily Open: Rethinking the rally
▼ + stars: | 2023-06-21 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Rally haltedU.S. markets closed in the red Tuesday, halting a rally that drove stocks to their highest levels in more than a year. The UK 'doom loop'The U.K. economy is trapped in a growth "doom loop," according to the country's Institute for Public Policy Research. The International Monetary Fund expects the U.K. economy to grow 0.4% this year.

Persons: Germany's DAX, Eli Lilly, Thali, Narendra Modi, Joe Biden, Biden, Tim Cook, Alphabet's Sundar Pichai, Satya Nadella, Raj Subramaniam, Goldman Sachs, Goldman Organizations: New York Stock Exchange, CNBC, Dice Therapeutics, country's Institute for Public Policy Research, Monetary Fund, U.S, House Locations: New York City, San Francisco, India, China

☆ Stocks making the biggest premarket moves: Alibaba, Dice Therapeutics, Avis and more
▼ + stars: | 2023-06-20 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Atmus Filtration Technologies — Shares of the air filtration company rose more than 2% after a slew of analysts initiated coverage with bullish ratings, including JPMorgan. The bank said Atmus trades at a "deep discounted valuation vs. peers, despite >80% of aftermarket mix, while its planned expansion into industrial filtration should bridge the valuation gap vs. direct filtration peers over time." Avis Budget — Shares added 3.5% in light volume following an upgrade by Morgan Stanley to overweight from equal weight. Philip Morris International — Shares of the tobacco company rose 1.5% in premarket trading after Citi upgraded Philip Morris to buy from neutral. Carnival — Shares moved 1.5% higher in the premarket, building on gains made last week when it was the S&P 500's best performer.

Persons: Daniel Zhang, Eddie Wu, Alibaba's, Eli Lilly, Morgan Stanley, Adam Jonas, Jonas, Avis, Philip Morris, —, Jesse Pound Organizations: Alibaba, Holding, JPMorgan, Avis Budget, Citi, Warner Bros Discovery Locations: Beijing, China, —

☆ Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
▼ + stars: | 2023-06-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Eli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up its treatment portfolio for immune-related diseases. Dice Therapeutics' share price jumped more than 37% to just under the purchase price. Auto-immune diseases can causes pain, fatigue, dizziness, depression and rashes, among other symptoms. There are more than 100 known autoimmune diseases, including lupus, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Eli Lilly's immunology portfolio includes drugs like Taltz, which treats plaque psoriasis, and Olumiant, a treatment for rheumatoid arthritis.

Persons: Eli Lilly, Eli Lilly's, Patrik Jonsson, Eli, Taltz Organizations: Dice Therapeutics Locations: Francisco

☆ Stocks making the biggest moves midday: Goldman Sachs, Avis, Rivian, Nike and more
▼ + stars: | 2023-06-20 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading. Goldman Sachs — Shares declined 2.2% in midday trading. Avis — The car rental company surged more than 6%. Chevron , ExxonMobil — Energy giants Chevron and ExxonMobil slipped more than 2% each in midday trading. Dice Therapeutics — Shares surged 37% after Eli Lilly said it was acquiring the biopharmaceutical company for $2.4 billion.

Persons: Goldman Sachs, Avis —, Morgan Stanley, Avis, Jay Sole, Rivian, Eli Lilly, Alibaba, Daniel Zhang, Wells, Biden, —, Jesse Pound, Alex Harring, Michelle Fox Theobald Organizations: UBS, Bank of America, Chevron, ExxonMobil — Energy, ExxonMobil, U.S . West Texas, Nike —, Rivian, Ford, GM, Intel, Bloomberg, Wall, JPMorgan Chase Locations: China, Brent, U.S, Germany, Wells Fargo, New York City

☆ Warren Buffett – he invests just like us!
▼ + stars: | 2023-06-07 | by ( Jeffrey Goldfarb | ) www.reuters.com time to read: +7 min

NEW YORK, June 7 (Reuters Breakingviews) - “Do as I say, not as I do” sounds like the kind of pithy thing Warren Buffett might say to his adoring throngs. The conglomerate was an investor for a dozen years, until Buffett got spooked by Freddie Mac’s overly rosy earnings growth projections. The $1.3 billion stake it finished accumulating in 1994 was worth $25 billion last month. A $13 billion stake in IBM (IBM.N) came and went, as did $8 billion of JPMorgan (JPM.N) and almost $3 billion of biopharmaceutical company AbbVie (ABBV.N). Warren Buffett, Berkshire’s chairman and CEO, said that geopolitical tensions contributed to the decision to sell most of the $4.1 billion TSMC stake just a few months after buying it, the Nikkei reported on April 11.

Persons: Warren Buffett, can’t, There’s, Buffett, Freddie Mac, Freddie Mac’s, Coke, Benjamin Moore, TSMC, ”, Wells, ” Buffett, Berkshire Hathaway, John Foley, Sharon Lam Organizations: YORK, Reuters, Berkshire Hathaway, Home Loan Mortgage, U.S ., Berkshire, BNSF, Taiwan Semiconductor Manufacturing, Buffett, ” Morningstar, Treasury, New York Stock Exchange, American Express, IBM, JPMorgan, Activision, Occidental Petroleum, Paramount Global, Oracle, Reuters Graphics Reuters, Nikkei, Thomson Locations: Berkshire, U.S, TSMC . Berkshire, Japan, Taiwan, Omaha, China

☆ Japan stocks are on fire this year. Here are 3 reasons why the rally could have 'staying power'
▼ + stars: | 2023-05-27 | by ( Sarah Min | ) www.cnbc.com time to read: +8 min

Since then, Japanese equities have rallied. Even so, Strategas Securities' Chris Verrone has remained optimistic on Japanese equities, saying this week that the rally is not yet overbought. Meanwhile, JPMorgan chief market strategist Marko Kolanovic said in a note, also on Tuesday, that the rally in Japan still has "staying power." For international investors, those remarks signaled that Japanese companies may be more transparent with shareholders in the future. Investors can also take a company-specific approach, according to Diamond Hill's Mohanraj, who favors Japanese companies that boast differentiated products.

☆ A stock trader who's returned 2,700% since late-2020 details the chart pattern he uses to rapidly trade risky small caps
▼ + stars: | 2023-05-17 | by ( Laila Maidan | ) www.businessinsider.com time to read: +9 min

Eduardo Briceno uses a few strategies to trade risky small-cap stocks. Eduardo Briceno had always wanted to take up a career in finance or work in the stock market as a broker. He started day trading full-time in 2017 after moving to the US from Venezuela. There aren't as many institutions that trade penny and small-cap stocks regularly compared to larger names, Sykes said. Although the framework is created for penny stocks, Briceno uses it to trade some small caps because he has observed a similar pattern play out within this category.

☆ Stocks making the biggest moves midday: Horizon Therapeutics, Capital One, RH, Home Depot and more
▼ + stars: | 2023-05-16 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Western Alliance Bancorp — Western Alliance shares jumped 3.6% after Bank of America reinstated coverage on the stock with a buy rating. Home Depot , Lowe's — Shares of home improvement retailers Home Depot and Lowe's lost 1.4% and 1% in midday trading Tuesday. On Monday, Daniel Welch, a director at Seagen, disclosed the sale of 1,864 shares, a stake worth more than $370,000. GE HealthCare — The medtech company's shares gained nearly 3% after Oppenheimer initiated coverage with an outperform rating on Monday. GE HealthCare separated from parent company General Electric earlier in 2023 and began publicly trading on the Nasdaq Jan. 4.

As earnings season continues, Wall Street analysts are raising their outlook for certain names set to report earnings next week. Against this backdrop, CNBC Pro used FactSet data to screen for companies reporting next week that analysts have been getting more bullish on. Overall, analyst earnings estimates for Incyte are up 48% over the past three months and nearly 13% over the past six months. On average, analysts have hiked their earnings per share estimates on the company by 46% over the past six months and 27% in the past three months. The cloud software company's earnings estimates have gone up 32% over the past six months.

☆ Stocks making the biggest moves midday: Southwest Airlines, Goldman Sachs, Bellus Health and more
▼ + stars: | 2023-04-18 | by ( Sarah Min | ) www.cnbc.com time to read: +4 min

PowerSchool Holdings – The educational technology stock added 3.5% after Goldman Sachs upgraded shares to buy from neutral. Bank of America – The bank stock was about flat even after the firm reported first-quarter earnings and revenue that topped expectations. Goldman Sachs – Shares slid 1.3% after Goldman Sachs reported first-quarter revenue of $12.22 billion, lower than the $12.79 billion forecasted by analysts polled by Refinitiv. The company reported adjusted earnings of $2.68 per share and revenue of $24.75 billion. Bellus Health, GSK – Bellus shares roughly doubled after GSK said it would acquire Canada-based biopharmaceutical company Bellus.

☆ Morningstar: Stocks are historically cheap — buy these 33 top undervalued names to brace for a volatile market today and profit from the recovery later this year
▼ + stars: | 2023-04-15 | by ( Lisa Kailai Han | ) www.businessinsider.com time to read: +5 min

In a recent note, Morningstar shared its top 33 undervalued stocks to buy for the second quarter. While the near term may look difficult for investors, Sekera believes that these headwinds will force the Federal Reserve to pump the brakes on its rate-hiking program sooner rather than later. Valuations-wise, small-cap firms remain the cheapest, while mid-cap and large-cap stocks respectively remain just below and above market average. In a separate note, Morningstar analysts listed their top 33 undervalued stocks for the second quarter of 2023. The full list of names is below, along with each company's ticker, sector, market capitalization, and price versus fair value estimate.

Search resuls for: "Biopharmaceutical"

25 mentions found